169 related articles for article (PubMed ID: 38232115)
1. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
Wang G; Fu J; Liu M; Zheng Q
PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
[TBL] [Abstract][Full Text] [Related]
2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
Front Oncol; 2021; 11():711402. PubMed ID: 34497764
[TBL] [Abstract][Full Text] [Related]
4.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
5. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
[TBL] [Abstract][Full Text] [Related]
6. Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma.
Fang X; Zhang T; Chen Z
Int J Gen Med; 2023; 16():481-497. PubMed ID: 36777097
[TBL] [Abstract][Full Text] [Related]
7. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
8. Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico analysis and clinical specimens validation via RT-qPCR and immunohistochemistry.
Li J; Ramzan F; Zhong G
Am J Cancer Res; 2023; 13(9):4376-4400. PubMed ID: 37818076
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
10. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
11. Significance analysis of PAX8 expression in endometrial carcinoma.
Hu S; Gan H; Yang F
Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161
[TBL] [Abstract][Full Text] [Related]
12. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
[TBL] [Abstract][Full Text] [Related]
13. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
14. Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma.
Shi M; Luo F; Shao T; Zhang H; Yang T; Wei Y; Chen R; Guo R
Front Cell Dev Biol; 2021; 9():793793. PubMed ID: 35155447
[TBL] [Abstract][Full Text] [Related]
15. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
[TBL] [Abstract][Full Text] [Related]
16. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.
Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F
Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211
[TBL] [Abstract][Full Text] [Related]
17. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
18. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
Liu ZS; Jing CL
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
[TBL] [Abstract][Full Text] [Related]
19. LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior.
Fu B; Zhou M; Geng X; Jiang Y; Zeng H; Zhou X; Yu Z; Pan J; Zhu Y; Zheng H; Huang S; Gong Y; Huang D; Zhong Y
Aging (Albany NY); 2024 Jan; 16(1):714-745. PubMed ID: 38217544
[TBL] [Abstract][Full Text] [Related]
20. Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
Pan Y; Jia LP; Liu Y; Han Y; Deng Q
J Ovarian Res; 2019 Aug; 12(1):81. PubMed ID: 31472672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
